Lv5
1000 积分 2021-08-02 加入
Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: A prospective, single-arm, phase II study (TD-NICE)
2年前
已完结
Local Control With Single-Fraction Lung Stereotactic Body Radiotherapy is not influenced by Non-Small Cell Lung Cancer Histologic Subtype
2年前
已完结
Gene of the month: lymphocyte-activation gene 3 (LAG-3)
2年前
已完结
Lymphocyte activation gene-3 (LAG-3) regulatory T cells: An evolving biomarker for treatment response in autoimmune diseases
2年前
已完结
[Progress on tumor immune checkpoints and their inhibitors in tumor therapy]
2年前
已关闭
Immunotherapy of cancer in the era of checkpoint inhibitor
2年前
已完结
Lag3: From Bench to Bedside
2年前
已完结
Perioperative ctDNA-Based Molecular Residual Disease Detection for Non–Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1)
2年前
已完结
A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study
2年前
已完结
Revisiting neoadjuvant therapy in non-small-cell lung cancer
2年前
已完结
皖公网安备34019202002308
